EZH2 and pachyonychia congenita: Our results underscore the importance of differentiating PC epigenome studies by histological subtype to enhance the efficacy of therapeutics targeting epigenetic regulators such as HDACs, KDMs, EZH2, ADAR1, or ZBP1.